Neuragain Finalizes Advisory Board For Groundbreaking Network Of Brain Health And Performance Doctors
BOSTON, Nov. 16, 2015 /PRNewswire/ -- Neuragain, LLC (www.neuragain.com & www.neuragainproviders.com), a network of doctors dedicated to offering Americans cutting edge brain health and performance treatments, has assembled a world-renowned Board of Advisors. The advisors will counsel Neuragain as it continues to build a network of psychiatrists, family physicians, internists and other medical providers offering state-of-the-art treatments to combat depression, anxiety and other conditions afflicting tens of millions of Americans.
"This team of advisors testifies to the extraordinary healing modalities our physicians will be offering patients and the extraordinary opportunity for practice growth which will be enjoyed by our participating physicians," said Henrik Sandell, PhD, CEO of Neuragain.
The Neuragain Advisory Board includes:
Alexander Vuckovic, MD
Dr. Vuckovic is board-certified in psychiatry and is a Distinguished Fellow of the American Psychiatric Association. He is Assistant Professor of Psychiatry at Harvard Medical School and is Medical Director of the Pavilion at McLean Hospital, a treatment and evaluation facility for patients with treatment-resistant psychiatric disorders.
Sanjiv Chopra, MD, M.A.C.P.
Dr. Chopra is Professor of Medicine at Harvard Medical School and the James Tullis Firm Chief in the Department of Medicine at Beth Israel Deaconess Medical Center. He served as Faculty Dean for Continuing Education at Harvard Medical School for 12 years. Chopra has more than 150 publications and seven books to his credit, including Brotherhood, co-written with his brother, Deepak Chopra, M.D.
James Clark
Mr. Clark has over 30 years experience in the fields of Pharmaceutical Delivery Systems Licensing and Business Development. He is a graduate of St. Joseph's University and served in the United States Navy, prior to beginning his business career.
In 1992 Mr. Clark founded Pharma Delivery Systems Inc. (PDS). PDS identified, negotiated and closed more than 25 licensing and development agreements in the areas of oral sustained release tablets, transdermal delivery systems, needle-free injector devices and solubility enhancement technologies with worldwide leaders in their fields.
Erin Tolbert, RN, FNP
Erin Tolbert is a graduate of Vanderbilt University and a certified Family Nurse Practitioner. She is also the founder of MidlevelU, a thriving online community for nurse practitioners and physician assistants with over 90,000 readers per month. She appears regularly as a healthcare expert on networks such as The Fox News Channel and CNN discussing topics related to medicine and healthcare.
Keith Ablow, MD
Dr. Ablow is one of America's leading psychiatrists and the author of New York Times and USA Today bestselling books on treating depression and restoring optimal psychological well-being. He is a graduate of Brown University and the Johns Hopkins School of Medicine. He has served as an Instructor and Assistant Clinical Professor at Tufts University School of Medicine and is board-certified in adult, adolescent, and forensic psychiatry.
Neuragain has already signed up doctors in several states, including, New York, Florida and California.
ABOUT Neuragain, LLC: Neuragain empowers physicians and their patients to utilize treatment protocols that are safe and effective, free from the intercession of insurance companies whose motivations are fundamentally cost driven and increasingly at odds with the patient's best interest. Neuragain physicians deliver state-of-the-art care in their offices and offer patients a comfortable, familiar, and local, option for treatment protocols that, in the past, have required travel.
Now more than ever, patients with treatment resistant illnesses are empowered to take a proactive approach to restoring their good health. Neuragain physicians welcome the opportunity to work with informed health care consumers and are committed to providing an unparalleled patient experience and superior outcomes.
SOURCE Neuragain, LLC
Share this article